Means and methods for treatment evaluation

A method of detecting an expression product of a marker gene comprising:

• incubating a proteinaceous molecule to a sample from an individual, said proteinaceous molecule capable of specifically binding a protein encoded by a nucleic acid selected from the group consisting of a sequence as depicted in FIG. 1-18, a sequence as depicted in Table 1 and a sequence as depicted in Table 2, or a part or analogue thereof;
• and
• detecting binding between said proteinaceous molecule and said protein.

A method for determining whether an individual possesses a tumor cell and/or a site of angiogenesis, comprising:

• obtaining a sample from said individual;
• and
• determining whether said sample comprises an expression product of at least one marker gene.

A method of determining whether an individual possesses a non-hemopoietic tumor cell and/or a site of angiogenesis, said method comprising determining whether a hemopoietic cell from said individual comprises an altered amount of an expression product of a marker gene as compared with a reference value.

A method of detecting angiogenesis comprising detecting peripheral blood mononuclear cell expression of at least one of Keratin 14 sequence, TIE 1 sequence, a Salioadhesion or Siglec 1 sequence, a sequence as depicted in FIG. 2, FIG. 8 or FIG. 17, or a part or analogue thereof.

A method of determining the presence of a tumor cell in an individual comprising:

• obtaining a sample from said individual;
• and
• detecting the level of peripheral blood mononuclear cell expression of at least one of a Keratin 14 sequence, TIE 1 sequence, a Salioadhesion or Siglec 1 sequence, a sequence as depicted in FIG. 2, FIG. 8 or FIG. 17, or an analogue thereof.

A method of diagnosing presence of disease comprising comparing expression of an isolated Keratin 14 sequence, TIE 1 sequence, a Salioadhesion or Siglec 1 sequence, a sequence as depicted in FIG. 2, FIG. 8 or FIG. 17, or an analogue thereof in an individual to a reference value.

A diagnostic kit comprising a nucleic acid comprising a sequence selected from the group consisting of a sequence as depicted in FIGS. 1-18, Table 1, Table 2, or a part or analogue thereof, and a proteinaceous molecule capable of specifically binding a protein encoded by said nucleic acid or said part or analogue thereof.

A compound capable of altering the activity of at least one of Salioadhesion or Siglec 1, TIE 1, Keratin 14, and the expression of at least one of Salioadhesion or Siglec 1, TIE 1 and Keratin 14 in a cell.

A method of preparing a medicament comprising:

• identifying a compound capable of altering the activity of at least one of Salioadhesion or Siglec 1, TIE 1, Keratin 14, and the expression of at least one of Salioadhesion or Siglec 1, TIE 1 and Keratin 14 in a cell;
• and
• incorporating said identified compound into a medicament.